BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 31761620)

  • 1. Analysis of gene expression signatures identifies prognostic and functionally distinct ovarian clear cell carcinoma subtypes.
    Tan TZ; Ye J; Yee CV; Lim D; Ngoi NYL; Tan DSP; Huang RY
    EBioMedicine; 2019 Dec; 50():203-210. PubMed ID: 31761620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.
    Ye S; Zhou S; Wu Y; Pei X; Jiang W; Shi W; Yang W; Zhou X; Shan B; Yang H
    Ann Med; 2023 Dec; 55(1):2218104. PubMed ID: 37272300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical significance of targeting drug-based molecular biomarkers expression in ovarian clear cell carcinoma].
    Li MJ; Li HR; Cheng X; Bi R; Tu XY; Liu F; Chen LH
    Zhonghua Fu Chan Ke Za Zhi; 2017 Dec; 52(12):835-843. PubMed ID: 29325268
    [No Abstract]   [Full Text] [Related]  

  • 4. The Potential Role of Complement System in the Progression of Ovarian Clear Cell Carcinoma Inferred from the Gene Ontology-Based Immunofunctionome Analysis.
    Su KM; Lin TW; Liu LC; Yang YP; Wang ML; Tsai PH; Wang PH; Yu MH; Chang CM; Chang CC
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clearer view on ovarian clear cell carcinoma.
    De Pauw A; Naert E; Van de Vijver K; Philippe T; Vandecasteele K; Denys H
    Acta Clin Belg; 2022 Aug; 77(4):792-804. PubMed ID: 34404331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue factor pathway inhibitor‑2 is specifically expressed in ovarian clear cell carcinoma tissues in the nucleus, cytoplasm and extracellular matrix.
    Ota Y; Koizume S; Nakamura Y; Yoshihara M; Takahashi T; Sato S; Myoba S; Ohtake N; Kato H; Yokose T; Miyagi E; Miyagi Y
    Oncol Rep; 2021 Mar; 45(3):1023-1032. PubMed ID: 33650653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.
    Zhu C; Zhu J; Qian L; Liu H; Shen Z; Wu D; Zhao W; Xiao W; Zhou Y
    BMC Cancer; 2021 Mar; 21(1):322. PubMed ID: 33766002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.
    Yanaihara N; Noguchi Y; Saito M; Takenaka M; Takakura S; Yamada K; Okamoto A
    PLoS One; 2016; 11(9):e0162584. PubMed ID: 27612152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and survival characteristic of mismatch repair status in ovarian clear cell carcinoma.
    Zhu J; Ke G; Bi R; Wu X
    J Surg Oncol; 2020 Sep; 122(3):538-546. PubMed ID: 32396667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma.
    Zhu J; Wen H; Bi R; Wu Y; Wu X
    J Gynecol Oncol; 2017 Nov; 28(6):e77. PubMed ID: 29027395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over-expression of RALYL suppresses the progression of ovarian clear cell carcinoma through inhibiting MAPK and CDH1 signaling pathways.
    Xia Y; Ye S; Yang Y; Liu Y; Tong G
    Int J Med Sci; 2021; 18(3):785-791. PubMed ID: 33437214
    [No Abstract]   [Full Text] [Related]  

  • 13. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
    Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
    J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.
    Chao A; Lai CH; Wang TH; Jung SM; Lee YS; Chang WY; Yang LY; Ku FC; Huang HJ; Chao AS; Wang CJ; Chang TC; Wu RC
    J Mol Med (Berl); 2018 Jun; 96(6):527-536. PubMed ID: 29725737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic and therapeutic impact of the chromosome 20q13.2 ZNF217 locus amplification in ovarian clear cell carcinoma.
    Rahman MT; Nakayama K; Rahman M; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Cancer; 2012 Jun; 118(11):2846-57. PubMed ID: 22139760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of Chromatin Remodeling Genes and the Rho GTPases
    Arildsen NS; Jönsson JM; Bartuma K; Ebbesson A; Westbom-Fremer S; Måsbäck A; Malander S; Nilbert M; Hedenfalk IA
    Front Oncol; 2017; 7():109. PubMed ID: 28611940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
    Yamaguchi K; Mandai M; Oura T; Matsumura N; Hamanishi J; Baba T; Matsui S; Murphy SK; Konishi I
    Oncogene; 2010 Mar; 29(12):1741-52. PubMed ID: 20062075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.
    Rauh-Hain JA; Davis M; Clemmer J; Clark RM; Growdon WB; Goodman AK; Boruta DM; Schorge JO; del Carmen MG
    Gynecol Oncol; 2013 Nov; 131(2):404-9. PubMed ID: 24004647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation sequencing shows the genomic features of ovarian clear cell cancer and compares the genetic architectures of high-grade serous ovarian cancer and clear cell carcinoma in ovarian and endometrial tissues.
    Gan M; Tai Z; Yu Y; Zhang C; Xu J
    PeerJ; 2023; 11():e14653. PubMed ID: 36721777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the presence of endometriosis associated with a survival benefit in pure ovarian clear cell carcinoma?
    Sahin H; Sari ME; Cuylan ZF; Haberal AN; Sirvan L; Coban G; Yalcin I; Güngör T; Celik H; Meydanli MM; Ayhan A
    Arch Gynecol Obstet; 2018 Apr; 297(4):1005-1013. PubMed ID: 29383437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.